References
- Brennan FM, Maini RN, Feldmann M. TNF alpha: a pivotal role in rheumatoid arthritis. Br J Rheumatol 1992; 31: 293–8
- Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004; 200: 367–76
- Pimentel-Muiños FX, Seed B. Regulated commitment of receptor signaling: a molecular switch for death or activation. Immunity 1999; 11: 783–93
- Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Jr, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991; 88: 9292–6
- MacEwan DJ. TNF ligands and receptors: a matter of life and death. Br J Pharmacol 2002; 135: 855–75
- Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11
- Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 2003; 42(Suppl 2)ii11–16
- Oregón-Romero E, Vázquez-Del Mercado M, Navarro-Hernández RE, Torres Carrillo N, Martínez-Bonilla G, Estrada-Garcia I, et al. Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels in clinical features. Rheumatol Int 2006; 27: 53–9
- Oregón-Romero E, Vázquez-Del Mercado M, Ruiz-Quezada SL, Navarro-Hernández RE, Rangel-Villalobos H, Martínez-Bonilla G, et al. Tumor necrosis factor alpha −308 and −238 polymorphisms in rheumatoid arthritis. Association with mRNA expression and sTNF alpha. J Invest Med 2008; 56: 937–43
- Sennels H, Sørensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 2008; 37: 241–7
- Guler H, Turhanoglu AD, Ozer B, Ozer C, Balci A. The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37: 337–42
- Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37: 173–8
- Klimiuk PA, Sierakowski S, Latosiewictz R, Cilwik JP, Cilwik B, Skowronski J, et al. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003; 62: 472–5
- Turan B, Pfister K, Diener PA, Hell M, Moller B, Boyvat A, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scand J Rheumatol 2008; 37: 135–41
- Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45–65
- Cope AP, Maini RN. Soluble tumor necrosis factor receptors in arthritis. J Rheumatol 1995; 22: 382–4
- Vandebabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 392–8